Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20719 | 1.00 | SIGMAR1 (0.78) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL65364 | 1.00 | SIGMAR1 (0.78) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL21315849 | 0.98 | SIGMAR1 (0.76) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL21315850 | 0.98 | SIGMAR1 (0.76) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL5639480 | 0.92 | SIGMAR1 (0.67) | SIGMAR1ALDH1A1 | |
| SCHEMBL3494735 | 0.88 | SIGMAR1 (0.80) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL4836976 | 0.88 | SIGMAR1 (0.80) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2419294 | 0.86 | SIGMAR1 (0.60) | SIGMAR1LMNA | |
| SCHEMBL5710391 | 0.86 | SIGMAR1 (0.60) | SIGMAR1LMNAPOLBGAA | |
| SCHEMBL21315846 | 0.85 | SIGMAR1 (0.59) | SIGMAR1LMNAPOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776859-B2 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776859-B2 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776859-B2 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070088039-A1 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088039-A1 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088039-A1 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088039-A1 | Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function | AR, FSHR, NR5A1 | SIGMAR1 168/4885LMNA 4059/4885POLB 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.